(Q40291094)

19 September 2017

title

Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist (English)

1 reference

19 September 2017

0 references

Joseph W Gunnet

1

1 reference

19 September 2017

Jay M Matthews

2

1 reference

19 September 2017

Bruce E Maryanoff

3

1 reference

19 September 2017

Lawrence de Garavilla

4

1 reference

19 September 2017

Patricia Andrade-Gordon

5

1 reference

19 September 2017

Bruce Damiano

6

1 reference

19 September 2017

William Hageman

7

1 reference

19 September 2017

Richard Look

8

1 reference

19 September 2017

Paul Stahle

9

1 reference

19 September 2017

Anthony J Streeter

10

1 reference

19 September 2017

Pamela G Wines

11

1 reference

19 September 2017

Keith T Demarest

12

1 reference

19 September 2017

publication date

1 April 2006

1 reference

Clinical and Experimental Pharmacology and Physiology

19 September 2017

published in

1 reference

19 September 2017

volume

33

1 reference

19 September 2017

issue

4

1 reference

19 September 2017

page(s)

320-326

1 reference

Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Vasopressin: a new target for the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Vasopressin V2 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Vasopressin antagonists in CHF: ready for clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Natriuretic peptides in the evaluation of suspected heart failure: studies in primary care are needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Impaired coronary flow and left ventricular dysfunction after mechanical recanalization in acute myocardial infarction: role of neurohumoral activation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

The effect of the maze procedure on the secretion of arginine-vasopressin and aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2006.04369.X

10.1111/J.1440-1681.2006.04369.X

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference